Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1–28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28-day cycles (CYKLONE regimen). Carfilzomi...

Full description

Saved in:
Bibliographic Details
Published in:Br J Haematol
Main Authors: Mikhael, Joseph R., Reeder, Craig B., Libby, Edward N., Costa, Luciano J., Bergsagel, P. Leif, Buadi, Francis, Mayo, Angela, Nagi Reddy, Sravan K., Gano, Katherine, Dueck, Amylou C., Stewart, A. Keith
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521972/
https://ncbi.nlm.nih.gov/pubmed/25683772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13296
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items